메뉴 건너뛰기




Volumn 22, Issue 18, 2004, Pages 3700-3704

Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB; AC PROTOCOL; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

EID: 4644232608     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.03.516     Document Type: Article
Times cited : (119)

References (19)
  • 1
    • 0032437869 scopus 로고    scopus 로고
    • Paclitaxel in breast cancer
    • Perez EA: Paclitaxel in breast cancer. Oncologist 3:373-389, 1998
    • (1998) Oncologist , vol.3 , pp. 373-389
    • Perez, E.A.1
  • 2
    • 0037445132 scopus 로고    scopus 로고
    • Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
    • Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
    • (2003) J Clin Oncol , vol.21 , pp. 976-983
    • Henderson, I.C.1    Berry, D.A.2    Demetri, G.D.3
  • 3
    • 0035752985 scopus 로고    scopus 로고
    • Side effects of chemotherapy and combined chemo-hormonal therapy in women with early-stage breast cancer
    • Partridge AH, Burstein HJ, Winer EP: Side effects of chemotherapy and combined chemo-hormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr 30:135-142, 2001
    • (2001) J Natl Cancer Inst Monogr , vol.30 , pp. 135-142
    • Partridge, A.H.1    Burstein, H.J.2    Winer, E.P.3
  • 4
    • 0021878134 scopus 로고
    • Early and delayed clinical cardiotoxicity of doxorubicin
    • Buzdar AU, Marcus C, Smith TL, et al: Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55:2761-2765, 1985
    • (1985) Cancer , vol.55 , pp. 2761-2765
    • Buzdar, A.U.1    Marcus, C.2    Smith, T.L.3
  • 5
    • 0041883701 scopus 로고    scopus 로고
    • Cardiotoxic effects of anthracycline-taxane combinations
    • Perotti A, Cresta S, Grasselli G, et al: Cardiotoxic effects of anthracycline-taxane combinations. Expert Opin Drug Saf 2:59-71, 2003
    • (2003) Expert Opin Drug Saf , vol.2 , pp. 59-71
    • Perotti, A.1    Cresta, S.2    Grasselli, G.3
  • 6
    • 0036498781 scopus 로고    scopus 로고
    • Cardiac dysfunction in the trastuzumab clinical trials experience
    • Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002
    • (2002) J Clin Oncol , vol.20 , pp. 1215-1221
    • Seidman, A.1    Hudis, C.2    Pierri, M.K.3
  • 7
    • 0036784463 scopus 로고    scopus 로고
    • Trastuzumab-associated cardiotoxicity
    • Keefe DL: Trastuzumab-associated cardiotoxicity. Cancer 95:1592-1600, 2002
    • (2002) Cancer , vol.95 , pp. 1592-1600
    • Keefe, D.L.1
  • 8
    • 0034872172 scopus 로고    scopus 로고
    • Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer
    • Gianni L, Dombernowsky P, Sledge G, et al: Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer. Ann Oncol 12:S63-S68, 2001 (suppl 1)
    • (2001) Ann Oncol , vol.12 , Issue.SUPPL. 1
    • Gianni, L.1    Dombernowsky, P.2    Sledge, G.3
  • 9
    • 0011715451 scopus 로고    scopus 로고
    • First report of the European Cooperative Trial in Operable Breast Cancer (ECTO): Effects of primary systemic therapy (PST) on local-regional disease
    • abstr 132
    • Gianni L, Baselga J, Eiermann W, et al: First report of the European Cooperative Trial in Operable Breast Cancer (ECTO): Effects of primary systemic therapy (PST) on local-regional disease. Proc Am Soc Clin Oncol 21:34a, 2002 (abstr 132)
    • (2002) Proc Am Soc Clin Oncol , vol.21
    • Gianni, L.1    Baselga, J.2    Eiermann, W.3
  • 10
    • 0035890811 scopus 로고    scopus 로고
    • Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer
    • Perez EA, Vogel CL, Irwin DH, et al: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216-1223, 2001
    • (2001) J Clin Oncol , vol.19 , pp. 4216-11223
    • Perez, E.A.1    Vogel, C.L.2    Irwin, D.H.3
  • 11
    • 0035873815 scopus 로고    scopus 로고
    • Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
    • Seidman AD, Fornier MN, Esteva FJ, et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587-2595, 2001
    • (2001) J Clin Oncol , vol.19 , pp. 2587-2595
    • Seidman, A.D.1    Fornier, M.N.2    Esteva, F.J.3
  • 12
    • 0001136449 scopus 로고    scopus 로고
    • Weekly paclitaxel (P) followed by FAC in the neo-adjuvant setting provides improved pathologic complete remission (PCR) rates compared to standard paclitaxel followed by FAC therapy-preliminary results of an ongoing prospective randomized trial
    • abstr 129
    • Green MC, Buzdar AU, Smith T, et al: Weekly paclitaxel (P) followed by FAC in the neo-adjuvant setting provides improved pathologic complete remission (PCR) rates compared to standard paclitaxel followed by FAC therapy-preliminary results of an ongoing prospective randomized trial. Proc Am Soc Clin Oncol 20:33a, 2001 (abstr 129)
    • (2001) Proc Am Soc Clin Oncol , vol.20
    • Green, M.C.1    Buzdar, A.U.2    Smith, T.3
  • 13
    • 21844480293 scopus 로고    scopus 로고
    • CALGB 9840: Phase 111 study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized to T in HER2 normal MBC
    • Seidman AD, Berry D, Cirrincione C, et al: CALGB 9840: Phase 111 study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized to T in HER2 normal MBC. Proc Am Soc Clin Oncol 22:65, 2004
    • (2004) Proc Am Soc Clin Oncol , vol.22 , pp. 65
    • Seidman, A.D.1    Berry, D.2    Cirrincione, C.3
  • 14
    • 18744395754 scopus 로고    scopus 로고
    • Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study
    • Burstein HJ, Harris LN, Gelman R, et al: Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study. J Clin Oncol 21:46-53, 2003
    • (2003) J Clin Oncol , vol.21 , pp. 46-53
    • Burstein, H.J.1    Harris, L.N.2    Gelman, R.3
  • 15
    • 0347995045 scopus 로고    scopus 로고
    • Pilot trial of trastuzumab starting with or after doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER-2 positive advance breast cancer
    • Bianchi G, Albanell J, Eiermann W, et al: Pilot trial of trastuzumab starting with or after doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER-2 positive advance breast cancer. Clin Cancer Res 9:5944-5951, 2003
    • (2003) Clin Cancer Res , vol.9 , pp. 5944-5951
    • Bianchi, G.1    Albanell, J.2    Eiermann, W.3
  • 16
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 17
    • 0035152095 scopus 로고    scopus 로고
    • Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation
    • Zambetti M, Moliterni A, Materazzo C, et al: Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 19:37-43, 2001
    • (2001) J Clin Oncol , vol.19 , pp. 37-43
    • Zambetti, M.1    Moliterni, A.2    Materazzo, C.3
  • 19
    • 0141799967 scopus 로고    scopus 로고
    • Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival
    • Woodward WA, Strom EA, Tucker SL, et al: Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 21:3244-3248, 2003
    • (2003) J Clin Oncol , vol.21 , pp. 3244-3248
    • Woodward, W.A.1    Strom, E.A.2    Tucker, S.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.